Arrowhead presents Phase 3 SHASTA-3/4 data for plozasiran in severe hypertriglyceridemia
Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data on plozasiran for patients with severe hypertriglyceridemia.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.